Treatment of basal cell carcinoma with vismodegib: future or present?
Jos VellemanOuti KaarelaJan J VranckxPublished in: Acta chirurgica Belgica (2019)
Vismodegib cannot replace complex reconstructions. However, in unresectable laBCC, Vismodegib can provide a bridge to surgery. Due to the possibility of persistent tumour cells, we recommend imaging-assisted surgery and an imaging-based follow-up. In case of complete clinical remission after Vismodegib in a neoadjuvant setting, we recommend that Vismodegib be continued as long as the adverse effects are tolerated and an imaging-based follow-up is advised.
Keyphrases
- basal cell carcinoma
- high resolution
- minimally invasive
- coronary artery bypass
- induced apoptosis
- lymph node
- rectal cancer
- computed tomography
- squamous cell carcinoma
- cell cycle arrest
- cell death
- signaling pathway
- surgical site infection
- oxidative stress
- coronary artery disease
- fluorescence imaging
- photodynamic therapy
- smoking cessation